["alzheimer's disease", 'dementia with lewy bodies', "parkinson's disease dementia"]
['rvt-101 35 mg', 'placebo']

        Key Inclusion Criteria:

        Male or female subject with a clinical diagnosis of Alzheimer's disease (AD), dementia with
        Lewy bodies (DLB), or Parkinson's disease dementia (PDD).

        Mini Mental State Examination score 14 to 26 Gait impairment, as assessed by history
        gathered by the clinical investigator and quantitative measurements Subjects must be on
        stable background acetylcholinesterase inhibitor therapy

        Key Exclusion Criteria:

        History and/or evidence of any other CNS disorder that could be interpreted as a cause of
        dementia (in the opinion of the investigator) Any clinically relevant concomitant disease
        which, in the opinion of the investigator, makes the subject unsuitable for inclusion in
        the study.
      